Race for a COVID-19 antibody treatment halted
NCT ID NCT04644185
Summary
This study tested if a lab-made antibody drug called SCTA01 could help hospitalized adults with severe COVID-19 get better faster. It compared the drug plus standard care against a placebo plus standard care. The trial was designed in two parts to find the best dose and then test its effectiveness, but it was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SCT study site
Somers Point, New Jersey, 08244, United States
-
SCT study site
Buenos Aires, Argentina
-
SCT study site
Uberlândia, Brazil
-
SCT study site
Talca, Chile
-
SCT study site
Rionegro, Colombia
-
SCT study site
Monterrey, Mexico
-
SCT study site
Lima, Peru
Conditions
Explore the condition pages connected to this study.